Charles River Laboratories International, Inc. (CRL)
After hours: 05:32PM EDT
| Previous Close | 412.52 |
| Open | 416.25 |
| Bid | 421.12 x 1000 |
| Ask | 421.42 x 800 |
| Day's Range | 413.92 - 423.59 |
| 52 Week Range | 219.79 - 460.21 |
| Volume | 188,295 |
| Avg. Volume | 331,526 |
| Market Cap | 21.239B |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | 54.42 |
| EPS (TTM) | 7.74 |
| Earnings Date | Nov. 03, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 449.18 |
- Business Wire
Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge
CAMBRIDGE, Mass., October 20, 2021--Charles River expands CRADL facilities in Cambridge, including growth of Binney Street site and the addition of a location on Bent Street.
- Zacks
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
- Business Wire
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
WILMINGTON, Mass., October 18, 2021--Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions. Cryo-EM is a technique that determines the 3D structures of proteins and is utilized to identify how proteins function, how they malfunction in disease and the most effective way to target them with therapies.
